North America Human Papilloma Virus/HPV Test and Pap Smear/Test Market (2025-2030)
The North America Human Papilloma Virus/HPV Test and Pap Smear/Test Market was valued at $744.7 Million in 2025 and projected to reach to $1152 Million by 2030, representing a compound annual growth rate of 9.1%. North America's HPV Test and Pap Smear market is poised for sustained expansion through 2030, driven by evolving clinical guidelines favoring HPV-based primary screening and the region's commitment to cervical cancer elimination.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America Human Papilloma Virus/HPV Test and Pap Smear/Test Market Trends and Insights
- In North America, increasing awareness of cervical cancer prevention and the shift toward HPV-based screening protocols are driving market expansion.
- North America's healthcare infrastructure and favorable reimbursement policies support widespread adoption of advanced diagnostic technologies. The North America market benefits from strong clinical evidence supporting HPV testing as a primary screening method, replacing traditional Pap smears in many healthcare settings.
- North America's aging population and emphasis on preventive care further accelerate demand for these diagnostic solutions.
- By 2030, North America is expected to maintain its position as a mature, high-value market with continued innovation in testing methodologies and automation..
Key Market Statistics
- CAGR (2025-2030) 9.1% CAGR
- Market Size, 2025 ~USD 744.7 Million
- Forecast, 2030 ~USD 1152 Million
- Geography North America
North America Human Papilloma Virus/HPV Test and Pap Smear/Test Market Overview
Market Valuation & Growth :
North America's HPV Test and Pap Smear market is valued at $744.7 million in 2025, with a robust 9.1% CAGR projected through 2030, reaching $1,152.0 million by forecast end.
HPV-Based Screening Adoption :
The region is experiencing a significant shift from traditional Pap smear protocols toward HPV-based screening methodologies, driven by superior clinical efficacy and improved cervical cancer prevention outcomes.
Cervical Cancer Prevention Awareness :
Increasing public and healthcare provider awareness of cervical cancer prevention strategies is accelerating screening uptake across North America, supported by robust healthcare infrastructure and insurance coverage.
Advanced Healthcare Infrastructure :
North America's well-established diagnostic laboratory networks, digital health integration, and reimbursement frameworks are enabling rapid adoption of next-generation HPV testing technologies and liquid-based cytology solutions.
North America Human Papilloma Virus/HPV Test and Pap Smear/Test Market Dynamics
- Healthcare systems across the US and Canada are increasingly transitioning from cytology-only approaches to HPV-centric protocols, supported by strong reimbursement policies and patient education initiatives.
- The market will benefit from technological innovations in molecular diagnostics, automation in laboratory workflows, and integration with electronic health records systems.
- Demographic shifts, including aging populations requiring continued screening, combined with improved access to preventive care, will further accelerate market penetration and revenue growth throughout the forecast period..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- North America's HPV Test and Pap Smear Market is valued at $744.7 million in 2025 and will reach $1,152.0 million by 2030, growing at a 9.1% CAGR.
- North America's shift from Pap smear-only screening to HPV-based primary screening is reshaping diagnostic demand and clinical protocols.
- North America's robust healthcare infrastructure and reimbursement landscape enable rapid adoption of advanced HPV testing technologies.
- North America's market is driven by preventive care initiatives, aging demographics, and strong clinical evidence supporting HPV testing efficacy.
Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | VAGINAL CANCER SCREENING (Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 10% from 2025 to 2030 |
| Largest Segment | CERVICAL CANCER SCREENING (Application) |
| Market Size Base Year (Billions) | ~USD 2.45 (2025) |
| Revenue Forecast (Billions) | ~USD 3.94 (2030) |
| Segments Covered | Product & Service, Test Type, Type, Technology, Application, Care Setting |
North America Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product & Service
- Consumables
- Instruments
- Services
By Test Type
- Hpv Testing
- Pap Tests
By Type
- Co-Testing
- Follow-Up Hpv Testing
- Primary Hpv Testing
By Technology
- Cytology
- Immunodiagnostics
- Molecular Diagnostics
By Application
- Cervical Cancer Screening
- Vaginal Cancer Screening
By Care Setting
- Diagnostic Laboratories
- Hospitals
- Physicians’ Offices & Clinics
Target Audience
- Diagnostic Equipment Manufacturers : Manufacturers of HPV testing platforms and Pap smear automation systems need North America market data to optimize product development, identify adoption barriers, and strategically position offerings within the region's evolving screening landscape.
- Clinical Laboratory Networks : Laboratory operators and pathology groups require market insights to benchmark performance, understand competitive positioning, plan capacity investments, and align service offerings with shifting HPV-based screening protocols.
- Healthcare System Administrators : Hospital networks and integrated healthcare providers need regional market intelligence to inform screening program investments, budget planning, technology procurement decisions, and cervical cancer prevention strategy development.
- In Vitro Diagnostics (IVD) Companies : IVD manufacturers and reagent suppliers require detailed North America market data to guide product launches, market entry strategies, pricing models, and sales force allocation across the US and Canadian markets.
- Healthcare Policy & Investment Professionals : Policy makers, healthcare investors, and venture capital firms need comprehensive market analysis to evaluate investment opportunities, assess market growth potential, and understand regulatory and reimbursement dynamics in North America.
Key Companies in the North America Human Papilloma Virus/HPV Test and Pap Smear/Test Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOMERIEUX S.A. | France | Public Company | Microbiology & AST (VITEK 2, VITEK MS, VITEK REVEAL, API, ETEST, CHROMID, culture media),Molecular & Syndromic (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, BIOMERIEUX EPISEQ CS),Immunoassay & Sepsis (VIDAS, Hybiome CLIA), |
| INTERTEK GROUP PLC | United Kingdom | Public Company | Consumer Products,Corporate Assurance,Health and Safety, |
| QUIDEL CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care, |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, localization, software),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa, CoolSeal), |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and molecular diagnostics assays,PCR and digital PCR solutions, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and single-use solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables), |
| ABBOTT | United States | Public Company | Medical Devices,Diagnostic Products,Nutritional Products, |
| SEEGENE INC. | South Korea | Public Company | Respiratory infectious disease panels,Sexually transmitted infection and HPV assays,Gastrointestinal and meningitis syndromic panels, |
| SD BIOSENSOR, INC. | South Korea | Public Company | STANDARD Q rapid diagnostics,STANDARD F fluorescence immunodiagnostics,STANDARD E enzyme immunoassay, |
| SANSURE BIOTECH INC. | China | Public Company | Nucleic acid diagnostic reagents (respiratory, HPV, reproductive, blood-borne, GI, others),Rapid antigen tests,Nucleic acid extraction and purification kits, sample reagents, |
| MOLBIO DIAGNOSTICS LIMITED | India | Private Company | Truenat PCR platforms (instruments),Truenat assays and reagents,Disposable POCT devices (dengue, malaria, COVID-19, others), |
BIOMERIEUX S.A.
bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company specializes in in vitro diagnostics and microbiology testing solutions.
INTERTEK GROUP PLC
Intertek Group PLC is a British public company established in 1885 with 45,425 employees. The company offers testing, inspection, and certification services across multiple industries.
QUIDEL CORPORATION
Quidel Corporation is a United States public company founded in 1979 with 6,500 employees. The company manufactures rapid diagnostic testing products and molecular assays.
HOLOGIC, INC.
Hologic, Inc. is a private United States company founded in 1985 with 7,070 employees. The company develops and manufactures diagnostic and medical imaging products.
QIAGEN
QIAGEN is a Dutch public company founded in 1984 with 5,500 employees. The company provides molecular diagnostics, sample preparation, and life sciences research tools.
DANAHER CORPORATION
Danaher Corporation is a United States public company founded in 1969 with 59,000 employees. The company operates across diagnostics, life sciences, and environmental solutions.
ABBOTT
Abbott is a United States public company founded in 1888 with 115,000 employees. The company is a diversified healthcare company providing diagnostics, medical devices, and pharmaceuticals.
SEEGENE INC.
Seegene Inc. is a South Korean public company founded in 2000 with 216 employees. The company specializes in molecular diagnostic testing and multiplex PCR technology.
SD BIOSENSOR, INC.
SD Biosensor, Inc. is a South Korean public company founded in 1999 with 576 employees. The company develops and manufactures rapid diagnostic test kits and point-of-care devices.
SANSURE BIOTECH INC.
Sansure Biotech Inc. is a Chinese public company founded in 2008 with 2,128 employees. The company develops molecular diagnostic reagents and testing solutions.
MOLBIO DIAGNOSTICS LIMITED
Molbio Diagnostics Limited is a private Indian company founded in 2000. The company develops and manufactures molecular diagnostic devices and testing solutions.
Countries within North America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| US | USD 1436 Million |
| Canada | USD 86.6 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Sizing & Forecasts : Obtain precise market valuations for North America ($744.7M in 2025) with country-level breakdowns for the US and Canada, enabling accurate budget allocation and revenue projections for regional expansion strategies.
- Screening Protocol Transition Insights : Understand the shift from traditional Pap smear to HPV-based primary screening across North America, including adoption timelines, clinical guideline changes, and their impact on product demand and market dynamics.
- Competitive Landscape Analysis : Identify key market players, their market share, product portfolios, and strategic positioning within North America's HPV testing and Pap smear segments to inform competitive strategy and partnership opportunities.
- Reimbursement & Regulatory Framework : Access detailed analysis of US and Canadian reimbursement policies, insurance coverage patterns, and regulatory requirements that directly influence market accessibility, pricing strategies, and commercialization timelines.
- Growth Drivers & Market Opportunities : Leverage comprehensive insights into cervical cancer prevention awareness campaigns, healthcare infrastructure investments, and emerging technologies to identify high-potential market segments and expansion opportunities through 2030.
Frequently asked questions
What is the current market size of the HPV Test and Pap Smear Market in North America?
In 2025, North America's HPV Test and Pap Smear Market is valued at $744.7 million USD.
What is the projected market size for North America by 2030?
North America's HPV Test and Pap Smear Market is projected to reach $1,152.0 million USD by 2030.
What is the CAGR for North America's HPV Test and Pap Smear Market?
North America's market is expected to grow at a compound annual growth rate of 9.1% from 2025 to 2030.
Why is North America's HPV testing market growing faster than traditional Pap smear testing?
North America is experiencing a clinical shift toward HPV-based primary screening due to superior sensitivity, better risk stratification, and strong clinical evidence supporting its efficacy in cervical cancer prevention.
What factors are driving market growth in North America?
North America's market growth is driven by preventive care initiatives, aging demographics, favorable reimbursement policies, healthcare infrastructure maturity, and widespread adoption of HPV testing guidelines by major health organizations.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global HPV testing and Pap test market.
Exhaustive secondary research was done to collect information on the HPV testing and Pap test market. The next step was to validate these findings, assumptions, and sizes with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the HPV testing and Pap test market.
Four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the HPV testing and Pap test market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:
- The key players in the industry have been identified through extensive secondary research.
- The revenues generated by leading players operating in the HPV testing and Pap test market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size included the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Human Papillomavirus (HPV) testing identifies the presence of high-risk HPV strains that can lead to cervical cancer and related abnormalities. It is increasingly adopted as a primary screening approach, either independently or alongside Pap testing (co-testing), to assess the risk of cervical disease.
The Papanicolaou (Pap) test is a cytological screening procedure used to detect precancerous and cancerous cells in the cervix, which connects the uterus and vagina. While primarily applied in cervical cancer screening, Pap tests can also detect abnormal or malignant cells in the vaginal canal in some cases.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global HPV testing and Pap test market by product & service, test type, technology, application, care setting, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall HPV testing and Pap test market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the HPV testing and Pap test market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region
Get the Full Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report
Full forecast, segment splits, and company analysis for all Human Papilloma Virus/HPV Test and Pap Smear/Test Market.
- US Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Canada Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Germany Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- UK Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- France Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Italy Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Spain Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- China Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Japan Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- India Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Brazil Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Mexico Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Saudi Arabia Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- UAE Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Asia Pacific Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Latam Human Papilloma Virus/HPV Test and Pap Smear/Test Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
